Ulrika Andersson

3.8k total citations
54 papers, 2.9k citations indexed

About

Ulrika Andersson is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Nutrition and Dietetics. According to data from OpenAlex, Ulrika Andersson has authored 54 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Cardiology and Cardiovascular Medicine, 11 papers in Internal Medicine and 9 papers in Nutrition and Dietetics. Recurrent topics in Ulrika Andersson's work include Atrial Fibrillation Management and Outcomes (29 papers), Cardiac Arrhythmias and Treatments (13 papers) and Venous Thromboembolism Diagnosis and Management (11 papers). Ulrika Andersson is often cited by papers focused on Atrial Fibrillation Management and Outcomes (29 papers), Cardiac Arrhythmias and Treatments (13 papers) and Venous Thromboembolism Diagnosis and Management (11 papers). Ulrika Andersson collaborates with scholars based in Sweden, United States and Canada. Ulrika Andersson's co-authors include Lars Wallentin, Ziad Hijazi, Agneta Siegbahn, Renato D. Lópes, Christopher B. Granger, John H. Alexander, Jonas Oldgren, Stefan H. Hohnloser, Michael D. Ezekowitz and Stuart J. Connolly and has published in prestigious journals such as Journal of Biological Chemistry, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Ulrika Andersson

52 papers receiving 2.8k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Ulrika Andersson 2.0k 636 366 324 288 54 2.9k
K.K. Talwar 1.4k 0.7× 53 0.1× 405 1.1× 380 1.2× 179 0.6× 190 3.1k
Petra Jilma‐Stohlawetz 402 0.2× 157 0.2× 240 0.7× 132 0.4× 102 0.4× 53 1.9k
Charles L. Campbell 925 0.5× 126 0.2× 228 0.6× 207 0.6× 72 0.3× 21 1.7k
Marie E. Steiner 311 0.2× 108 0.2× 330 0.9× 250 0.8× 132 0.5× 122 2.9k
James E. Sidaway 507 0.2× 110 0.2× 1.2k 3.2× 256 0.8× 476 1.7× 28 2.1k
D.A. Reaveley 402 0.2× 43 0.1× 398 1.1× 114 0.4× 194 0.7× 33 1.9k
Claire Bal dit Sollier 702 0.3× 284 0.4× 198 0.5× 107 0.3× 58 0.2× 63 1.3k
A Barsotti 491 0.2× 79 0.1× 164 0.4× 74 0.2× 148 0.5× 59 1.2k
Andrea De Gottardi 154 0.1× 114 0.2× 1.3k 3.6× 2.8k 8.5× 566 2.0× 99 4.9k
M. Różalski 423 0.2× 112 0.2× 293 0.8× 74 0.2× 34 0.1× 56 1.1k

Countries citing papers authored by Ulrika Andersson

Since Specialization
Citations

This map shows the geographic impact of Ulrika Andersson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulrika Andersson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulrika Andersson more than expected).

Fields of papers citing papers by Ulrika Andersson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulrika Andersson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulrika Andersson. The network helps show where Ulrika Andersson may publish in the future.

Co-authorship network of co-authors of Ulrika Andersson

This figure shows the co-authorship network connecting the top 25 collaborators of Ulrika Andersson. A scholar is included among the top collaborators of Ulrika Andersson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulrika Andersson. Ulrika Andersson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hijazi, Ziad, Paolo Verdecchia, Jonas Oldgren, et al.. (2019). Cardiac biomarkers and left ventricular hypertrophy in relation to outcomes in patients with atrial fibrillation: Experiences from the RE-LY trial. IrInSubria (University of Insubria). 15 indexed citations
3.
Horowitz, John D., Raffaele De Caterina, Tamila Heresztyn, et al.. (2018). Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 72(7). 721–733. 31 indexed citations
4.
Hijazi, Ziad, Stefan H. Hohnloser, Jonas Oldgren, et al.. (2018). Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE-LY trial analysis. American Heart Journal. 198. 169–177. 11 indexed citations
5.
Caterina, Raffaele De, Ulrika Andersson, John H. Alexander, et al.. (2016). History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. American Heart Journal. 175. 175–183. 17 indexed citations
6.
Siegbahn, Agneta, Jonas Oldgren, Ulrika Andersson, et al.. (2016). D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy. Thrombosis and Haemostasis. 115(5). 921–930. 46 indexed citations
7.
Hijazi, Ziad, S. H. Hohnloser, Ulrika Andersson, et al.. (2015). Efficacy and safety of apixaban compared with warfarin in relation to renal function over time in patients with atrial fibrillation : Insights from the ARISTOTLE trial. European Heart Journal. 36. 339–339. 7 indexed citations
8.
Sandhu, Roopinder K., Justin A. Ezekowitz, Ulrika Andersson, et al.. (2015). BODY MASS INDEX AND OUTCOMES WITH APIXABAN VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION IN THE ARISTOTLE (APIXABAN FOR REDUCTION IN STROKE AND OTHER THROMBOEMBOLIC EVENTS IN ATRIAL FIBRILLATION) TRIAL. Journal of the American College of Cardiology. 65(10). A284–A284. 6 indexed citations
9.
Christersson, Christina, Lars Wallentin, Ulrika Andersson, et al.. (2014). The efficacy of apixaban compared to warfarin in patients with atrial fibrillation with high coagulation activity despite anticoagulant treatment. European Heart Journal. 35. 866–867. 1 indexed citations
10.
Hijazi, Ziad, Ulrika Andersson, Bernard J. Gersh, et al.. (2014). Interleukin-6 and C-reactive protein and risk for cardiovascular events and death in anticoagulated patients with atrial fibrillation. European Heart Journal. 35. 1115–1116. 1 indexed citations
11.
Christersson, Christina, Lars Wallentin, Ulrika Andersson, et al.. (2014). D‐dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation – observations from the ARISTOTLE trial. Journal of Thrombosis and Haemostasis. 12(9). 1401–1412. 80 indexed citations
12.
Hijazi, Ziad, Lars Wallentin, Agneta Siegbahn, et al.. (2013). N-Terminal Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 61(22). 2274–2284. 173 indexed citations
13.
Hijazi, Ziad, Lars Wallentin, Agneta Siegbahn, et al.. (2013). High-Sensitivity Troponin T and Risk Stratification in Patients With Atrial Fibrillation During Treatment With Apixaban or Warfarin. Journal of the American College of Cardiology. 63(1). 52–61. 120 indexed citations
14.
Hijazi, Ziad, Jonas Oldgren, Ulrika Andersson, et al.. (2012). Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation. Circulation. 125(13). 1605–1616. 304 indexed citations
15.
Andersson, Ulrika, Estera Szwajcer Dey, Cecilia Holm, & Eva Degerman. (2011). Rye bran alkylresorcinols suppress adipocyte lipolysis and hormone‐sensitive lipase activity. Molecular Nutrition & Food Research. 55(S2). S290–3. 31 indexed citations
16.
Eikelboom, John W., Ziad Hijazi, Jonas Oldgren, et al.. (2010). Abstract 18321: D-dimer is Prognostic for Stroke, Major Bleeding and Death During Anticoagulation of Atrial Fibrillation - a RELY Substudy. Circulation. 122. 2 indexed citations
17.
Hijazi, Ziad, Jonas Oldgren, Ulrika Andersson, et al.. (2010). Abstract 13472: NT-proBNP is Prognostic for Stroke and Death in Atrial Fibrillation - a RELY Substudy. Circulation. 122. 3 indexed citations
18.
Andersson, Ulrika, Siv Ahrné, G. Molin, et al.. (2010). Probiotics lower plasma glucose in the high-fat fed C57BL/6J mouse. Beneficial Microbes. 1(2). 189–196. 91 indexed citations
19.
Rosén, Liza, et al.. (2009). Endosperm and whole grain rye breads are characterized by low post-prandial insulin response and a beneficial blood glucose profile. Nutrition Journal. 8(1). 42–42. 129 indexed citations
20.
Andersson, Ulrika, Fredrik Levander, & Peter Rådström. (2001). Trehalose-6-phosphate Phosphorylase Is Part of a Novel Metabolic Pathway for Trehalose Utilization in Lactococcus lactis. Journal of Biological Chemistry. 276(46). 42707–42713. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by K.K. Talwar Breakdown of academic impact, for papers by Petra Jilma‐Stohlawetz Breakdown of academic impact, for papers by Charles L. Campbell Breakdown of academic impact, for papers by Marie E. Steiner Breakdown of academic impact, for papers by James E. Sidaway Breakdown of academic impact, for papers by D.A. Reaveley Breakdown of academic impact, for papers by Claire Bal dit Sollier Breakdown of academic impact, for papers by A Barsotti Breakdown of academic impact, for papers by Andrea De Gottardi Breakdown of academic impact, for papers by M. Różalski
Rankless by CCL
2026